DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The population of dementia is increasing rapidly. Cognitive impairment as well as Behavioral
and psychological symptoms of dementia (BPSD) add heavy burdens to caregiver. NMDA activation
is critical for learning and memory. Individuals with Alzheimer's disease (AD) have fewer
NMDA receptors in the frontal cortex and hippocampus than controls. This study is a
randomized, double-blind, placebo-controlled drug trial. All patients will be allocated
randomly to two groups: (1) NMDA enhancer: DAOIB (starting dosage: 250-500 mg/day), (2)
placebo, for 6 weeks. The investigators hypothesize that DAOIB may yield better efficacy than
placebo for cognitive function and clinical symptoms in patients with BPSD.